DK3077372T3 - Ror-gamma-modulatorer - Google Patents

Ror-gamma-modulatorer Download PDF

Info

Publication number
DK3077372T3
DK3077372T3 DK14809794.2T DK14809794T DK3077372T3 DK 3077372 T3 DK3077372 T3 DK 3077372T3 DK 14809794 T DK14809794 T DK 14809794T DK 3077372 T3 DK3077372 T3 DK 3077372T3
Authority
DK
Denmark
Prior art keywords
phenyl
acetamide
hexafluoro
hydroxypropan
sulfonyl
Prior art date
Application number
DK14809794.2T
Other languages
English (en)
Inventor
Joseph Maria Gerardus Barbara Cals
Sander Bernardus Nabuurs
Original Assignee
Lead Pharma Holding Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lead Pharma Holding Bv filed Critical Lead Pharma Holding Bv
Application granted granted Critical
Publication of DK3077372T3 publication Critical patent/DK3077372T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C07C317/46—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/20—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C07C317/48—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (28)

1. Forbindelse med formlen I 0'Rs Ris^L-Rfs Aj3 ''''Au-II I A-m,^, An .N. .O R4 R10 rs ii |T^ Rg'^^'Y’X^ R8 R’ O Ri Meta eller para (Formel I) eller farmaceutisk acceptabelt salt deraf, hvor An - A14 er N eller henholdsvis CRu, CR12, CR-13, CR14 med det forbehold, at ikke mere end to af de fire positioner A samtidigt kan være N Ri er C(1-6)alkyl, C(3-6)cycloalkyl, C(3-6)cycloalkylC(1-3)alkyl, (di)C(1-6)alkylamino, hvor (di)C-(1-6)alkylamino som anvendt heri betyder en aminogruppe, som uafhængigt er monosubstitueret eller disubstitueret med H eller C(1-6)alkylgruppe(r) og, når (di)C(1-6)alkylaminogrupper indeholder to C(1-6)alkylgrupper, kan en af C(1-6)alkylgrupperne erstattes af en C(3-6)cycloalkylgruppe, (di)C(3-6)cycloalkylamino, hvor (di)C(3-6)cycloalkylamino som anvendt heri betyder en aminogruppe, som uafhængigt er monosubstitueret eller disubstitueret med H eller C(3-6)cycloalkylgruppe(r), og når (di)C(3-6)cycloalkylaminogrupperne indeholder to (C3-6)cycloalkylgrupper, kan en af C(3-6)cycloalkylgrupperne erstattes af en C(1-6)alkylgruppe, eller (di)(C(3-6)cycloalkylC(1-3)alkyl)amino, hvor (di)(C(3-6)cycloalkylC(1-3)alkyl)amino som anvendt heri betyder en aminogruppe, som uafhængigt er monosubstitueret eller disubstitueret med H eller C(3-6)cycloalkylC(1-3)alkylgruppe(r), med alle carbonatomer i alkylgrupper, der eventuelt kan være substitueret med én eller flere F’er, og alle carbonatomer i cycloalkylgrupper, der eventuelt kan være substitueret med én eller flere F’er eller methyl R2 og R3 uafhængigt er H, F, methyl, ethyl, hydroxy eller methoxy, eller R2 og R3 sammen er carbonyl, idet alle alkylgrupperne, hvis de forefindes, eventuelt kan være substitueret med én eller flere F'er R4 er Fl eller C(1-6)alkyl R5 er H, hydroxyethyl, methoxyethyl, C(1-6)alkyl, C(6-10)aryl, C(6-10)arylC(1-3)alkyl, C(1-9)heteroaryl, C(1- 9)heteroarylC(1-3)alkyl, C(3-6)cycloalkyl, C(3-6)cycloalkylC(1-3)alkyl, C(2-5)heterocycloalkyl eller C(2- 5) heterocycloalkylC(1-3)alkyl, idet alle grupper eventuelt kan være substitueret med én eller flere F, Cl, C(1-2)alkyl, C(1-2)alkoxy eller cyano; sulfonylgruppen med Ri udgøres af én af R7, Rs eller R9 de resterende R6-Ri4 uafhængigt er H, halogen, C(1-3)alkoxy, (di)C(1- 3) alkylamino, hvor (di)C(1-3)alkylamino som anvendt heri betyder en aminogruppe, der uafhængigt er monosubstitueret eller disubstitueret med Fl eller C(1-3)alkylgruppe(r), eller C(1-6)alkyl, idet alle alkylgrupperne eventuelt kan være substitueret med én eller flere F'er, og R15 og R16 uafhængigt er H, C(1-6)alkyl, C(3-6)cycloalkyl, C(3- 6) cycloalkylC(1-3)alkyl, C(6-10) aryl, C(6-10)arylC(1-3)alkyl, C (1-9)heteroaryl, C(1 -9) heteroarylC(1-3)alkyl, C(2-5)heterocycloalkyl eller C(2-5)heterocycloalkylC(1-3)alkyl, idet alle grupper eventuelt kan være substitueret med én eller flere F, Cl, C(1-2)alkyl, C(1-2)alkoxy eller cyano.
2. Forbindelse ifølge krav 1, hvor Rier C(1-2)alkyl, cyclopropyl, C(3- 4) cycloalkylC(1-3)alkyl, methylamino eller C(3-4)cycloalkylamino.
3. Forbindelse ifølge krav 2, hvor Ri er ethyl, cyclopropylamino eller cyclopropylmethyl.
4. Forbindelse ifølge krav 3, hvor R-ι er cyclopropylamino eller cyclopropylmethyl.
5. Forbindelse ifølge krav 4, hvor R1 er cyclopropylmethyl.
6. Forbindelse ifølge krav 1-5, hvor R2og R3 uafhængigt er H, methyl eller hydroxy.
7. Forbindelse ifølge krav 6, hvor R2 og R3 uafhængigt er Fl eller methyl.
8. Forbindelse ifølge krav 1-7, hvor R4 er H eller C(1-2)alkyl.
9. Forbindelse ifølge krav 1-8, hvor R5 er H, hydroxyethyl, methoxyethyl eller C(1-6)alkyl, idet alle alkylgrupper eventuelt kan være substitueret med én eller flere F'er.
10. Forbindelse ifølge krav 9, hvor R5 er H eller C(1-3)alkyl.
11. Forbindelse ifølge krav 1-8, hvor R5 er C(6)arylC(1-3)alkyl eller C(3-6)cycloalkylC(1 -3)alkyl.
12. Forbindelse ifølge krav 11, hvor R5 er benzyl.
13. Forbindelse ifølge krav 1-12, hvor R6-Rio er H med det forbehold, at én af grupperne R7, Rs eller Rg er en sulfonylgruppe med R-i.
14. Forbindelse ifølge krav 13, hvor Rs er en sulfonylgruppe med R-i.
15. Forbindelse ifølge krav 1-12, hvor Rs er en sulfonylgruppe med R-ι, og hvor R-io er methyl, og de resterende R6, R7 og R9 er H.
16. Forbindelse ifølge krav 1 -15, hvor alle Αη-Α-ι4 er carbon.
17. Forbindelse ifølge krav 1-15, hvor enten An eller Ai2 er nitrogen, og de resterende An-Ai4 er carbon.
18. Forbindelse ifølge krav 1-17, hvor Rn-Ri4 uafhængigt er H, halogen, methyl eller methoxy.
19. Forbindelse ifølge krav 18, hvor Rn-Ri4 er H.
20. Forbindelse ifølge krav 1-19, hvor R15 er CF3 og R-i6 er H, C(1-6)alkyl, C(3-6)cycloalkyl eller C(3-6)cycloalkylC(1-3)alkyl.
21. Forbindelse ifølge krav 20, hvor R15 er CF3 og R-i6 er CF3, propyl, isopropyl, 2-methylpropyl, 2,2-dimethylpropyl, cyclopropyl, cyclopentyl eller cyclohexylmethyl.
22. Forbindelse ifølge krav 21, hvor både R15 og Rie er CF3.
23. Forbindelse ifølge krav 1, som er valgt fra den gruppe, der består af: N-(4-(1,1,1,3,3,3-hexafluor-2-hydroxypropan-2-yl)phenyl)-2-(4-(methylsulfonyl)phenyl)acetamid 2-(4-(ethylsulfonyl)phenyl)-N-(4-(1,1,1,3,3,3-hexafluor-2-hydroxypropan-2-yl) phenyl)acetamid N-(4-(1,1,1,3,3,3-hexafluor-2-hydroxypropan-2-yl)phenyl)-2-(4-(isopropyl sulfonyl)phenyl)acetamid N-(4-(1,1,1,3,3,3-hexafluor-2-hydroxypropan-2-yl)phenyl)-2-(4-(propylsulfonyl) phenyl)acetamid 2-(4-(ethylsulfonyl)phenyl)-N-(4-(1,1,1,3,3,3-hexafluor-2-hydroxypropan-2-yl) phenyl)propanamid N-(4-(1,1,1,3,3,3-hexafluor-2-hydroxypropan-2-yl)phenyl)-2-(4-(N-methylsulfamoyl)phenyl)acetamid N-(4-(1,1,1,3,3,3-hexafluor-2-hydroxypropan-2-yl)phenyl)-2-(4-(N-isopropylsulfamoyl)phenyl)acetamid 2-(4-(N-(cyclopropylmethyl)sulfamoyl)phenyl)-N-(4-(1,1,1,3,3,3-hexafluor-2-hydroxypropan-2-yl)phenyl)acetamid 2-(4-(N-cyclopropylsulfamoyl)phenyl)-N-(4-(1,1,1,3,3,3-hexafluor-2-hydroxypropan-2-yl)phenyl)acetamid 2-(4-(N-ethylsulfamoyl)phenyl)-N-(4-(1,1,1,3,3,3-hexafluor-2-hydroxypropan-2-yl)phenyl)acetamid 2-(4-(N,N-dimethylsulfamoyl)phenyl)-N-(4-(1,1,1,3,3,3-hexafluor-2-hydroxypropan-2-yl)phenyl)acetamid 2-(3-(N-cyclopropylsulfamoyl)phenyl)-N-(4-(1,1,1,3,3,3-hexafluor-2-hydroxypropan-2-yl)phenyl)acetamid 2-(3-(N-ethylsulfamoyl)phenyl)-N-(4-(1,1,1,3,3,3-hexafluor-2-hydroxypropan-2-yl)phenyl)acetamid 2-(3-(N,N-dimethylsulfamoyl)phenyl)-N-(4-(1,1,1,3,3,3-hexafluor-2-hydroxypropan-2-yl)phenyl)acetamid 2-(4-(ethylsulfonyl)phenyl)-N-(3-fluor-4-(1,1,1,3,3,3-hexafluor-2-hydroxypropan-2-yl)-2-methylphenyl)acetamid 2-(4-(N-cyclopropylsulfamoyl)phenyl)-N-(4-(1,1,1,3,3,3-hexafluor-2-hydroxypropan-2-yl)phenyl)-N-methylacetamid 2-(4-(N-cyclopropylsulfamoyl)phenyl)-N-ethyl-N-(4-(1,1,1,3,3,3-hexafluor-2-hydroxypropan-2-yl)phenyl)acetamid 2-(3-(N-cyclopropylsulfamoyl)phenyl)-N-(4-(1,1,1,3,3,3-hexafluor-2- hydroxypropan-2-yl)phenyl)-N-methylacetamid N-(4-(1,1,1,3,3,3-hexafluor-2-hydroxypropan-2-yl)phenyl)-2-(3-(N- methylsulfamoyl)phenyl)acetamid 2-(4-(ethylsulfonyl)phenyl)-N-(5-fluor-4-(1,1,1,3,3,3-hexafluor-2-hydroxypropan-2-yl)-2-methoxyphenyl)acetamid 2-(4-(ethylsulfonyl)phenyl)-N-(5-(1,1,1,3,3,3-hexafluor-2-hydroxypropan-2-yl)pyridin-2-yl)acetamid N-(5-chlor-4-(1,1,1,3,3,3-hexafluor-2-hydroxypropan-2-yl)-2-methoxyphenyl)-2-(4-(ethylsulfonyl)phenyl)acetamid 2-(4-(ethylsulfonyl)phenyl)-N-(4-(1,1,1,3,3,3-hexafluor-2-hydroxypropan-2-yl)-2,6-dimethylphenyl)acetamid 2-(3-(N-cyclobutylsulfamoyl)phenyl)-N-(4-(1,1,1,3,3,3-hexafluor-2-hydroxypropan-2-yl)phenyl)acetamid 2-(4-(N-cyclobutylsulfamoyl)phenyl)-N-(4-(1,1,1,3,3,3-hexafluor-2-hydroxy propan-2-yl)phenyl)acetamid 2-(4-(N-cyclopropylsulfamoyl)phenyl)-N-(3-fluor-4-(1,1,1,3,3,3-hexafluor-2- hydroxypropan-2-yl)-2-methylphenyl)acetamid N-(4-(1,1,1,3,3,3-hexafluor-2-hydroxypropan-2-yl)phenyl)-2-(4- (isobutylsulfonyl)phenyl)acetamid 2-(4-(ethylsulfonyl)phenyl)-N-(2-fluor-4-(1,1,1,3,3,3-hexafluor-2-hydroxypropan-2-yl)phenyl)acetamid 2- (4-(ethylsulfonyl)phenyl)-N-(4-(1,1,1,3,3,3-hexafluor-2-hydroxypropan-2-yl)- 3- methylphenyl)acetamid 2-(4-(ethylsulfonyl)phenyl)-N-(3-fluor-4-(1,1,1,3,3,3-hexafluor-2-hydroxypropan-2-yl)phenyl)acetamid 2-(4-(ethytsulfonyl)pheny))-N-(4-(1,1,1,3,3,3-hexafluor-2-hydroxypropan-2-yl)-2-methylphenyl)acetamid 2-(4-(N-cyclopropylsulfamoyl)phenyl)-N-(4-(1,1,1,3,3,3-hexafluor-2-hydroxypropan-2-yl)-3-methylphenyl)acetamid 2-(4-(N-cyclopropylsulfamoyl)phenyl)-N-(3-fluor-4-(1,1,1,3,3,3-hexafluor-2-hydroxypropan-2-yl)phenyl)acetamid 2-(4-(N-cyclopropylsulfamoyl)phenyl)-N-(4-(1,1,1,3,3,3-hexafluor-2-hydroxypropan-2-yl)-2-methylphenyl)acetamid 2-(4-(N-cyclopropylsulfamoyl)phenyl)-N-(2-fluor-4-(1,1,1,3,3,3-hexafluor-2-hydroxypropan-2-yl)phenyl)acetamid 2-(3-(N-cyclopropylsulfamoyl)phenyl)-N-(4-(1,1,1,3,3,3-hexafluor-2-hydroxypropan-2-yl)-3-methylphenyl)acetamid 2-(4-((cyclopropylmethyl)sulfonyl)phenyl)-N-(4-(1,1,1,3,3,3-hexafluor-2-hydroxypropan-2-yl)phenyl)acetamid 2-(3-(N-cyclopropylsulfamoyl)phenyl)-N-(3-fluor-4-(1,1,1,3,3,3-hexafluor-2-hydroxypropan-2-yl)phenyl)acetamid 2-(3-(N-cyclopropylsulfamoyl)phenyl)-N-(4-(1,1,1,3,3,3-hexafluor-2-hydroxypropan-2-yl)-2-methylphenyl)acetamid 2-(3-(N-cyclopropylsulfamoyl)phenyl)-N-(2-fluor-4-(1,1,1,3,3,3-hexafluor-2-hydroxypropan-2-yl)phenyl)acetamid 2-(3-(N-(cyclopropylmethyl)sulfamoyl)phenyl)-N-(4-(1,1,1,3,3,3-hexafluor-2-hydroxypropan-2-yl)phenyl)acetamid 2-(4-(ethylsulfonyl)-3-fluorphenyl)-N-(4-(1,1,1,3,3,3-hexafluor-2-hydroxypropan-2-yl)phenyl)acetamid 2-(4-((cyclopropylmethyl)sulfonyl)phenyl)-N-(4-(1,1,1,3,3,3-hexafluor-2-hydroxypropan-2-yl)-2-methylphenyl)acetamid 2-(4-((cydopropylmethy))sulfonyl)phenyl)-N-(4-(1,1,1,3,3,3-hexafluor-2-hydroxypropan-2-yl)-3-methylphenyl)acetamid 2-(4-((cyclopropylmethyl)sulfonyl)phenyl)-N-(3-fluor-4-(1,1,1,3,3,3-hexafluor-2-hydroxypropan-2-yl)phenyl)acetamid 2-(4-((cyclopropylmethyl)sulfonyl)phenyl)-N-(2-fluor-4-(1,1,1,3,3,3-hexafluor-2-hydroxypropan-2-yl)phenyl)acetamid 2-(4-(ethylsulfonyl)phenyl)-N-(4-(1,1,1,3,3,3-hexafluor-2-methoxypropan-2-yl)phenyl)acetamid N-(4-2-ethoxy-1,1,1,3,3,3-hexafluorpropan-2-yl)phenyl)-2-(4-(ethylsulfonyl)phenyl)acetamid 2-(4-(ethylsulfonyl)phenyl)-N-(4-(1,1,1,3,3,3-hexafluor-2-propoxypropan-2-yl)phenyl)acetamid N-(4-(2-(benzyloxy)-1,1,1,3,3,3-hexafluorpropan-2-yl)phenyl)-2-(4-(ethylsulfonyl)phenyl)acetamid 2-(4-((cyclopropylmethyl)sulfonyl)phenyl)-N-(4-(1,1,1,3,3,3-hexafluor-2- isopropoxypropan-2-yl)phenyl)acetamid N-(4-2-butoxy-1,1,1,3,3,3-hexafluorpropan-2-yl)phenyl)-2-(4- ((cyclopropylmethyl)sulfonyl)phenyl)acetamid 2-(4-((cyclopropylmethyl)sulfonyl)phenyl)-N-(4-(2-ethoxy-1,1,1,3,3,3- hexafluorpropan-2-yl)phenyl)acetamid 2-(4-((cyclopropylmethyl)sulfonyl)phenyl)-N-(4-(1,1,1,3,3,3-hexafluor-2-methoxypropan-2-yl)phenyl)acetamid 2-(4-((cyclopropylmethyl)sulfonyl)phenyl)-N-(4-(1,1,1,3,3,3-hexafluor-2- hydroxypropan-2-yl)-2-methoxyphenyl)acetamid 2-(4-(cyclopropylmethyl)sulfonyl)phenyl)-N-(4-(1,1,1,3,3,3-hexafluor-2- hydroxypropan-2-yl)-3-methoxyphenyl)acetamid N-(2-amino-4-(1,1,1,3,3,3-hexafluor-2-hydroxypropan-2-yl)phenyl)-2-(4- ((cyclopropylmethyl)sulfonyl)phenyl)acetamid N-(4-(2-(2-cyclopropylethoxy)-1,1,1,3,3,3-hexafluorpropan-2-yl)phenyl)-2-(4-((cyclopropylmethyl)sulfonyl)phenyl)acetamid N-(4-(2-(benzyloxy)-1,1,1,3,3,3-hexafluorpropan-2-yl)phenyl)-2-(4-((cyclopropylmethyl)sulfonyl)phenyl)acetamid 2-(4-((cyclopropylmethyl)sulfonyl)phenyl)-N-(4-(1,1,1,3,3,3-hexafluor-2-propoxypropan-2-yl)phenyl)acetamid 2-(4-(N-cyclopropylsulfamoyl)phenyl)-N-(4-(1,1,1,3,3,3-hexafluor-2-propoxypropan-2-yl)phenyl)acetamid N-(3-chlor-4-(1,1,1,3,3,3-hexafluor-2-hydroxypropan-2-yl)phenyl)-2-(4-((cyclopropylmethyl)sulfonyl)phenyl)acetamid 2-(4-(ethylsulfonyl)phenyl)-N-(4-(1,1,1 -trifluor-2-hydroxypentan-2-yl)phenyl)acetamid 2-(4-((cyclopropylmethyl)sulfonyl)phenyl)-N-(4-(1,1,1 -trifluor-2-hydroxyhexan-2-yl)phenyl)acetamid 2-(4-(ethylsulfonyl)phenyl)-N-(4-(1,1,1 -trifluor-2-hydroxy-3-methylbutan-2-yl)phenyl)acetamid 2-(4-(ethylsulfonyl)phenyl)-N-(4-(1,1,1 -trifluor-2-hydroxy-4-methylpentan-2-yl)phenyl)acetamid N-(4-(1-cyclopropyl-2,2,2-trifluor-1-hydroxyethyl)phenyl)-2-(4-((cyclopropylmethyl)sulfonyl)phenyl)acetamid N-(4-(3-cyclopentyl-1,1,1 -trifluor-2-hydroxypropan-2-yl)phenyl)-2-(4-((cyclopropylmethyl)sulfonyl)phenyl)acetamid N-(4-(3-cyclohexyl-1,1,1 -trifluor-2-hydroxypropan-2-yl)phenyl)-2-(4-((cyclopropylmethyl)sulfonyl)phenyl)acetamid 2-(4-((cyclopropylmethyl)sulfonyl)phenyl)-N-(4-(2,2,2-trifluor-1-hydroxyethyl)phenyl)acetamid 2-(4-((cyclopropylmethyl)sulfonyl)phenyl)-N-(4-(1,1,1 -trifluor-2-hydroxypropan-2-yl)phenyl)acetamid 2-(4-(ethylsulfonyl)phenyl)-N-(4-(1,1,1 -trifluor-2-hydroxyhexan-2-yl)phenyl)acetamid N-(4-(1-cyclopropyl-2,2,2-trifluor-1-hydroxyethyl)phenyl)-2-(4- (ethylsulfonyl)phenyl)acetamid N-(4-(3-cyclohexyl-1,1,1 -trifluor-2-hydroxypropan-2-yl)phenyl)-2-(4-(ethylsulfonyl)phenyl)acetamid N-(4-(1-cyclopentyl-2,2,2-trifluor-1-hydroxyethyl)phenyl)-2-(4- ((cyclopropylmethyl)sulfonyl)phenyl)acetamid 2-(4-(N-cyclopropylsulfamoyl)phenyl)-N-(4-(1,1,1 -trifluor-2-hydroxy-4-methylpentan-2-yl)phenyl)acetamid 2-(3-(N-cyclopropylsulfamoyl)phenyl)-N-(4-(1,1,1 -trifluor-2-hydroxy-4-methylpentan-2-yl)phenyl)acetamid 2-(4-(N-cyclopropylsulfamoyl)phenyl)-N-(4-(1,1,1 -trifluor-2-hydroxypropan-2-yl)phenyl)acetamid 2-(4-(N-cyclopropylsulfamoyl)phenyl)-N-(4-(1,1,1 -trifluor-2-hydroxybutan-2-yl)phenyl)acetamid 2-(4-(N-cyclopropylsulfamoyl)phenyl)-N-(4-(1,1,1 -trifluor-2-hydroxypentan-2-yl)phenyl)acetamid 2-(3-(N-cyclopropylsulfamoyl)phenyl)-N-(4-(1,1,1 -trifluor-2-hydroxypentan-2-yl)phenyl)acetamid 2-(4-(cyclopropylmethyl)sulfonyl)phenyl)-N-(4-(1,1,1 -trifluor-2-hydroxy-4,4-dimethylpentan-2-yl)phenyl)acetamid 2-(4-((cyclopropylmethyl)sulfonyl)phenyl)-N-(4-(1,1,1 -trifluor-2-hydroxybutan-2-yl)phenyl)acetamid N-(3-chlor-4-(1,1,1,3,3,3-hexafluor-2-hydroxypropan-2-yl)phenyl)-2-(4-(ethylsulfonyl)phenyl)acetamid N-(4-(1-cyclopentyl-2,2,2-trifluor-1-hydroxyethyl)phenyl)-2-(4- (ethylsulfonyl)phenyl)acetamid N-(4-(3-cyclopentyl-1,1,1 -trifluor-2-hydroxypropan-2-yl)phenyl)-2-(4-(ethylsulfonyl)phenyl)acetamid 2-(4-cyclopropylmethansulfonylphenyl)-N-[4-(1,1,1 -trifluor-2-hydroxy-3-phenylpropan-2-yl)phenyl]acetamid 2-(4-((cyclopropylmethyl)sulfonyl)phenyl)-N-(4-(2,2,2-trifluor-1-hydroxy-1- phenylethyl)phenyl)acetamid N-(3-chlor-4-(1,1,1,3,3,3-hexafluor-2-hydroxypropan-2-yl)phenyl)-2-(4-(N-cyclopropylsulfamoyl)phenyl)acetamid N-(4-(1-cyclopentyl-2,2,2-trifluor-1-hydroxyethyl)phenyl)-2-(4-(N-cyclopropylsulfamoyl)phenyl)acetamid N-(3-chlor-4-(1,1,1,3,3,3-hexafluor-2-hydroxypropan-2-yl)phenyl)-2-(3-(N-cyclopropylsulfamoyl)phenyl)acetamid N-(4-(1-cyclopentyl-2,2,2-trifluor-1-hydroxyethyl)phenyl)-2-(3-(N- cyclopropylsulfamoyl)phenyl)acetamid 2-(4-((cyclopropylmethyl)sulfonyl)-2-methylphenyl)-N-(4-1,1,1,3,3,3-hexafluor-2-hydroxypropan-2-yl)phenyl)acetamid 2-(4-(N-cyclopropylsulfamoyl)phenyl)-N-(4-(1,1,1 -trifluor-2-hydroxy-4,4-di methylpentan-2-yl)phenyl)acetamid 2-(4-(N-cyclopropylsulfamoyl)phenyl)-N-(4-(1,1,1 -trifluor-2-hydroxy-3-methylbutan-2-yl)phenyl)acetamid 2-(4-(ethylsulfonyl)phenyl)-N-(4-(1,1,1 -trifluor-2-hydroxy-4,4-dimethylpentan-2-yl)phenyl)acetamid 2-(4-(ethylsulfonyl)phenyl)-N-(4-(2,2,2-trifluor-1 -hydroxy-1 -phenylethyl)phenyl)acetamid N-(2-chlor-4-(1,1,1,3,3,3-hexafluor-2-hydroxypropan-2-yl)phenyl)-2-(4-((cyclopropylmethyl)sulfonyl)phenyl)acetamid N-(4-(3-cyclopentyl-1,1,1 -trifluor-2-hydroxypropan-2-yl)phenyl)-2-(4-(N-cyclopropylsulfamoyl)phenyl)acetamid N-(4-(3-cyclohexyl-1,1,1 -trifluor-2-hydroxypropan-2-yl)phenyl)-2-(4-(N-cyclopropylsulfamoyl)phenyl)acetamid 2-(4-(N-cyclopropylsulfamoyl)phenyl)-N-(4-(2,2,2-trifluor-1-hydroxy-1 -phenylethyl)phenyl)acetamid 2-(4-((cyclopropylmethyl)sulfonyl)phenyl)-N-(4-(1,1,1,3,3,3-hexafluor-2-hydroxypropan-2-yl)phenyl)-2-oxoacetamid 2-(4-((cydopropylmethy)sulfonyl)phenyl)-N-(4-(2-hydroxypropan-2-yl)phenyl)acetamid 2-(4-(cyclopropylmethyl)sulfonyl)phenyl)-N-(4-(1,1,1 -trifluor-2-hydroxy-5-methylhexan-2-yl)phenyl)acetamid 2-(4-(N-cyclopropylsulfamoyl)phenyl)-N-(5-fluor-4-(1,1,1,3,3,3-hexafluor-2- hydroxypropan-2-yl)-2-methoxyphenyl)acetamid 2-(4-((cyclopropylmethyl)sulfonyl)phenyl)-N-(4- (dicyclopropyl(hydroxy)methyl)phenyl)acetamid 2-(4-((cyclopropylmethyl)sulfonyl)phenyl)-N-(5-(1,1,1,3,3,3-hexafluor-2- hydroxypropan-2-yl)pyridin-2-yl)acetamid 2-(4-((cyclopropylmethyl)sulfonyl)phenyl)-N-(4-(1,1,1 -trifluor-2-hydroxy-6-methylheptan-2-yl)phenyl)acetamid 2-(4-((cyclopropylmethyl)sulfonyl)phenyl)-N-(4-(1,1,1,3,3,3-hexafluor-2-hydroxypropan-2-yl)phenyl)propanamid 2-(4-((cyclopropylmethyl)sulfonyl)phenyl)-N-(6-(1,1,1,3,3,3-hexafluor-2-hydroxypropan-2-yl)pyridin-3-yl)acetamid 2-(4-(ethylsulfonyl)phenyl)-N-(6-(1,1,1,3,3,3-hexafluor-2-hydroxypropan-2-yl) pyridin-3-yl)acetamid 2-(4-(ethylsulfonyl)phenyl)-N-(4-(1,1,1,3,3,3-hexafluor-2-(2,2,2-trifluorethoxy)propan-2-yl)phenyl)acetamid 2-(4-((cyclopropylmethyl)sulfonyl)phenyl)-N-(4-(1,1,1,3,3,3-hexafluor-2-(2,2,2-trifluorethoxy)propan-2-yl)phenyl)acetamid og 2-(4-((cyclopropylmethyl)sulfonyl)phenyl)-N-(4-(1,1,1,3,3,3-hexafluor-2-hydroxypropan-2-yl)phenyl)-2-hydroxyacetamid.
24. Forbindelse ifølge krav 23, som er 2-(4-((cyclopropylmethyl)sulfonyl)phenyl)-N-(4-(1,1,1,3,3,3-hexafluor-2-hydroxypropan-2-yl)phenyl)acetamid.
25. Forbindelse ifølge et hvilket som helst af kravene 1 til 24 eller farmaceutisk acceptabelt salt deraf til anvendelse i terapi.
26. Forbindelse ifølge et hvilket som helst af kravene 1 til 24 eller farmaceutisk acceptabelt salt deraf til anvendelse til behandling af RO Rymedierede sygdomme eller tilstande.
27. Farmaceutisk sammensætning, der omfatter en forbindelse med formel I ifølge et af kravene 1 til 24 eller et farmaceutisk acceptabelt salt deraf og et eller flere farmaceutisk acceptable excipienser.
28. Farmaceutisk sammensætning ifølge krav 27, der desuden omfatter mindst ét yderligere terapeutisk aktivt middel.
DK14809794.2T 2013-12-05 2014-12-03 Ror-gamma-modulatorer DK3077372T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13195813 2013-12-05
EP14183274 2014-09-02
PCT/EP2014/076390 WO2015082533A1 (en) 2013-12-05 2014-12-03 Ror gamma (rory) modulators

Publications (1)

Publication Number Publication Date
DK3077372T3 true DK3077372T3 (da) 2019-04-23

Family

ID=52021176

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14809794.2T DK3077372T3 (da) 2013-12-05 2014-12-03 Ror-gamma-modulatorer

Country Status (29)

Country Link
US (1) US9738600B2 (da)
EP (1) EP3077372B8 (da)
JP (1) JP6461960B2 (da)
KR (1) KR102251128B1 (da)
CN (1) CN105980353B (da)
AU (1) AU2014359324B2 (da)
CA (1) CA2932483C (da)
CL (1) CL2016001364A1 (da)
CR (1) CR20160303A (da)
DK (1) DK3077372T3 (da)
DO (1) DOP2016000125A (da)
EA (1) EA030393B1 (da)
ES (1) ES2722409T3 (da)
HR (1) HRP20190483T1 (da)
HU (1) HUE043258T2 (da)
IL (1) IL246018B (da)
LT (1) LT3077372T (da)
MX (1) MX368721B (da)
MY (1) MY179106A (da)
PE (1) PE20160891A1 (da)
PH (1) PH12016501066A1 (da)
PL (1) PL3077372T3 (da)
PT (1) PT3077372T (da)
RS (1) RS58650B1 (da)
SI (1) SI3077372T1 (da)
TN (1) TN2016000224A1 (da)
UA (1) UA117941C2 (da)
WO (1) WO2015082533A1 (da)
ZA (1) ZA201604043B (da)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ724602A (en) * 2014-03-27 2022-12-23 Piramal Entpr Ltd Ror-gamma modulators and uses thereof
AU2015248466A1 (en) * 2014-04-16 2016-09-15 Glenmark Pharmaceuticals S.A. Aryl and heteroaryl ether compounds as ROR gamma modulators
PT3212641T (pt) 2014-10-30 2019-02-11 Janssen Pharmaceutica Nv Tiazoles como moduladores de rorãt
CN108064224B (zh) 2014-10-30 2022-03-29 詹森药业有限公司 作为Rorγt的调节剂的酰胺取代的噻唑
JOP20200117A1 (ar) 2014-10-30 2017-06-16 Janssen Pharmaceutica Nv كحولات ثلاثي فلوروميثيل كمُعدلات للمستقبل النووي جاما تي المرتبط بحمض الريتيونَويك ROR?t
CN107614062A (zh) 2015-03-12 2018-01-19 加利福尼亚大学董事会 用RORγ抑制剂治疗癌症的方法
CN113121497A (zh) 2015-05-15 2021-07-16 奥瑞基尼探索技术有限公司 用作RORγ调节剂的经过取代的四氢喹啉酮化合物
WO2016193894A1 (en) * 2015-05-29 2016-12-08 Glenmark Pharmaceuticals S.A. Treatment of respiratory disorders using ror- gamma inhibitors
EP3101008A1 (en) * 2015-06-05 2016-12-07 Lead Pharma Cel Models IP B.V. Ror gamma (rory) modulators
EP3101005A1 (en) * 2015-06-05 2016-12-07 Lead Pharma Cel Models IP B.V. Ror gamma (rory) modulators
WO2017010399A1 (ja) * 2015-07-10 2017-01-19 塩野義製薬株式会社 ＲＯＲγｔ阻害作用を有する化合物およびそれらを含有する医薬組成物
TWI728017B (zh) 2015-12-15 2021-05-21 瑞典商阿斯特捷利康公司 異吲哚化合物、包含其之醫藥組成物及其用途
TW201803869A (zh) 2016-04-27 2018-02-01 健生藥品公司 作為ＲＯＲγＴ調節劑之６－胺基吡啶－３－基噻唑
AR109042A1 (es) * 2016-07-14 2018-10-24 Cadila Healthcare Ltd COMPUESTOS MODULARES DE RORg
JP2019520400A (ja) 2016-07-14 2019-07-18 カディラ ヘルスケア リミティド 新規シクロプロピル誘導体
US10196350B2 (en) * 2016-12-05 2019-02-05 Lead Pharma Holding B.V. ROR gamma (RORγ) modulators
WO2018116285A1 (en) * 2016-12-23 2018-06-28 Glenmark Pharmaceuticals S.A. Substituted morpholine derivatives as ror gamma modulators
JP2020524660A (ja) 2017-06-14 2020-08-20 アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ Ｒｏｒ−ガンマモジュレーターとして有用な２，３−ジヒドロイソインドール−１−カルボキサミド
JP2021528405A (ja) 2018-06-18 2021-10-21 ヤンセン ファーマシューティカ エヌ．ベー． ＲＯＲγｔのモジュレータとしてのアミド置換チアゾール
CA3103770A1 (en) 2018-06-18 2019-12-26 Janssen Pharmaceutica Nv Phenyl and pyridinyl substituted imidazoles as modulators of roryt
JP2021528398A (ja) 2018-06-18 2021-10-21 ヤンセン ファーマシューティカ エヌ．ベー． ＲＯＲγＴのモジュレーターとしての６−アミノピリジン−３−イルピラゾール
CN112292373A (zh) 2018-06-18 2021-01-29 詹森药业有限公司 作为RORγt的调节剂的吡啶基吡唑类
JP2022547617A (ja) * 2019-09-16 2022-11-14 ダイス アルファ，インク． Ｉｌ－１７ａモジュレーターおよびその使用
CN112759541B (zh) * 2019-10-21 2023-03-17 复旦大学 类吲哚衍生物及其用途
CN113072521B (zh) * 2020-01-06 2024-04-05 广东东阳光药业股份有限公司 RORγt抑制剂及其在药物中的应用
TW202136238A (zh) * 2020-01-06 2021-10-01 大陸商廣東東陽光藥業有限公司 RORγt抑制劑及其製備方法和用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011115892A1 (en) * 2010-03-15 2011-09-22 Griffin Patrick R Modulators of the retinoic acid receptor-related orphan receptors
WO2012027965A1 (en) * 2010-09-01 2012-03-08 Glaxo Group Limited Novel compounds
WO2013029338A1 (en) * 2011-09-01 2013-03-07 Glaxo Group Limited Novel compounds
EP2909189B8 (en) * 2012-10-16 2017-04-19 Janssen Pharmaceutica NV Heteroaryl linked quinolinyl modulators of ror-gamma-t
WO2013171729A2 (en) 2013-01-08 2013-11-21 Glenmark Pharmaceuticals S.A. Aryl and heteroaryl amide compounds as rorgamat modulator
KR20150128863A (ko) * 2013-03-15 2015-11-18 에프. 호프만-라 로슈 아게 RORc 조절제로서 아릴 설파미드 및 설파메이트 유도체
EP2781217A1 (en) * 2013-03-18 2014-09-24 ETH Zurich ROR gamma modulators

Also Published As

Publication number Publication date
CA2932483A1 (en) 2015-06-11
IL246018A0 (en) 2016-08-02
BR112016012663A2 (pt) 2017-08-08
WO2015082533A1 (en) 2015-06-11
TN2016000224A1 (en) 2017-10-06
US20160304448A1 (en) 2016-10-20
ES2722409T3 (es) 2019-08-09
MY179106A (en) 2020-10-28
EP3077372A1 (en) 2016-10-12
KR102251128B1 (ko) 2021-05-12
CN105980353B (zh) 2019-06-14
PT3077372T (pt) 2019-03-21
IL246018B (en) 2020-01-30
RS58650B1 (sr) 2019-05-31
EA201691173A1 (ru) 2016-11-30
JP2017504576A (ja) 2017-02-09
KR20160105413A (ko) 2016-09-06
PL3077372T3 (pl) 2019-09-30
PE20160891A1 (es) 2016-09-24
AU2014359324B2 (en) 2019-02-21
JP6461960B2 (ja) 2019-01-30
AU2014359324A1 (en) 2016-07-14
SI3077372T1 (sl) 2019-07-31
EP3077372B1 (en) 2019-02-06
EA030393B1 (ru) 2018-07-31
CR20160303A (es) 2016-11-10
UA117941C2 (uk) 2018-10-25
MX368721B (es) 2019-10-14
NZ721511A (en) 2020-10-30
MX2016007275A (es) 2017-01-05
HUE043258T2 (hu) 2019-08-28
CN105980353A (zh) 2016-09-28
HRP20190483T1 (hr) 2019-05-17
CL2016001364A1 (es) 2016-12-02
DOP2016000125A (es) 2016-08-31
ZA201604043B (en) 2017-08-30
PH12016501066A1 (en) 2016-07-11
CA2932483C (en) 2022-05-17
US9738600B2 (en) 2017-08-22
EP3077372B8 (en) 2019-04-10
LT3077372T (lt) 2019-03-25

Similar Documents

Publication Publication Date Title
DK3077372T3 (da) Ror-gamma-modulatorer
NZ714821A (en) Processes of making and crystalline forms of a mdm2 inhibitor
AU2016273351B2 (en) ROR gamma (RORy) modulators
EP3303291B1 (en) Ror-gamma modulators
AU2016273353B2 (en) ROR gamma (RORy) modulators
CA2988009C (en) Ror gamma (rory) modulators
JP2017504576A5 (da)
NZ714821B2 (en) Ror gamma (rory) modulators
NZ721511B2 (en) Ror gamma (rory) modulators
BR112016012663B1 (pt) Compostos do modulador ror gama (ror?), uso para a preparação de um medicamento para tratamento de doenças auto-imunes, doenças inflamatórias ou doenças infecciosas mediadas por ror? e composição farmacêutica compreendendo esses compostos
JP2012250973A (ja) ピリミドベンゾチアジン−６−イミン誘導体またはその塩を含有するウイルス感染症の治療および／または予防のための薬剤